APPENDIX 5

GUIDELINE ON REGISTRATION OF GENERICS

IMPORTANT NOTES:

This document shall be read in conjunction with the relevant sections of the main guidance document: **Drug Registration Guidance Document (DRGD)**, which is in accordance to the legal requirements of the **Sale of Drugs Act 1952** and the **Control of Drugs and Cosmetics Regulations 1984**.

1. DEFINITION

A generic product is a product that is essentially similar to a currently registered product in Malaysia. However, the term generic is not applicable to Biologics.

2. GENERIC APPLICATION

The following categories of product can be processed as generic application provided that it fulfils the definition of a generic product.

(i) **Scheduled Poison**

(Known as Controlled Medicine/ Controlled Poison)

Products containing active ingredients as listed in the First Schedule under Poisons Act 1952.

(ii) **Non-Scheduled Poison**

(Known as "Over-the-Counter", OTC)

Products containing active ingredients which are not listed in the First Schedule under Poisons Act 1952; and are excluding active ingredients which are categorized under health supplements or natural products or cosmetics.

(a) **Full Evaluation**

Other than listed at (b) Abridge Evaluation

(b) **Abridged Evaluation**

which include, but not limited to the following:

- Antiseptics/ skin disinfectants;
- Locally-acting lozenges/ pastilles;
- Topical analgesic/ counter-irritants;
- Topical nasal decongestants;
- Emollient/ demulcent/ skin protectants;
- Keratolytics;
- Anti-dandruff;
- Oral care;
- Anti-acne;
- Medicated plasters/ patch/ pad; and
- Topical antibacterial.

Medicinal Gas

For medicinal gases classified as generic products, please refer to Directive No. 8, 2021 and Guideline on Registration of Medicinal Gases.

Reference:

- Directive No. 8, 2021, NPRA.600-1/9/13 (18): *Direktif Berkenaan Pengukuhan Pelaksanaan Kawalan Regulatori Ke Atas Produk-Produk Gas Perubatan dan Penggunaan Guideline on Registration of Medicinal Gases* (11 February 2021)

3. SUBMISSION OF APPLICATION

Applicants are advised to refer to **Section A (5. Application Procedures)** of the DRGD for further explanation.

4. EVALUATION TIMELINE FOR GENERIC APPLICATION

Table 1: Evaluation Timeline for Generic Application

No.	Product Category	Evaluation Timeline
(A)	**Full Evaluation**	
	Generic (Schedule Poison)	**210 working days**
	Generic (Non-Schedule Poison)	**210 working days**
(B)	**Abridged Evaluation**	
	Generic (Non-Schedule Poison) (i) Single active ingredient (ii) Two (2) or more active ingredients	 **116 working days** **136 working days**

5. REQUIREMENTS FOR GENERIC APPLICATION

5.1 Please refer to the following Appendices supplemented together with the DRGD for further information, where applicable:

Appendix 9	Fees
Appendix 11	Regulatory Control of Active Pharmaceutical Ingredients (APIs)
Appendix 12	Priority Review
Appendix 13	Designation and Registration of Orphan Medicines
Appendix 14	Evaluation Routes
Appendix 15	Requirements for Full Evaluation and Abridged Evaluation
Appendix 16	Bioequivalence (BE) Requirements
Appendix 17	Product Names Not Permitted To Be Registered
Appendix 18	List of Permitted, Prohibited and Restricted Substances
Appendix 19	General Labelling Requirements
Appendix 19A	Prohibited Visual/ Graphics/ Statements on Label
Appendix 20	Specific Labelling Requirements
Appendix 21	Special Conditions for Registration of a Particular Product or Group of Products

Appendix 22	Educational Materials
Appendix 23	Patient Dispensing Pack for Pharmaceutical Products
Appendix 24	Appeal
Appendix 25	Guideline for the Submission of Protocol of Analysis (POA)
Appendix 26	Guideline for the Submission of Analytical Method Validation (AMV) Documents
Appendix 27	Inspection
Appendix 32	Explanatory Notes for Repackers

5.2 STABILITY DATA REQUIREMENTS

Stability data of Active Pharmaceutical Ingredients (APIs)

For requirements of stability data of APIs, kindly refer to Appendix 11: Regulatory Control of Active Pharmaceutical Ingredients (APIs).

Stability data of finished product

The submitted finished product stability data should be from batches manufactured at the finished product manufacturing site proposed for registration in Malaysia. At the time of submission of the new product application, the stability data requirements are summarized as follows:

Study conditions	Minimum data at the time of submission	Number of batches
Long term	6 months	Minimum 2 (at least pilot scale) for conventional dosage form and stable API
	12 months	Minimum 3 (primary batch) for critical dosage form or unstable API
Accelerated	6 months	Minimum 2 (at least pilot scale) for conventional dosage form and stable API
		Minimum 3 (primary batch) for critical dosage form or unstable API

Primary batch *refers to a batch used in a stability study, from which stability data are submitted in a registration application for the purpose of establishing a shelf-life. A primary batch of a for a finished*

product, two of the three batches should be at least pilot scale batch, and the third batch can be smaller if it is representative with regard to the critical manufacturing steps. However, a primary batch may be a production batch. - ICH Q1A(R2)

Where possible, batches of the finished product should be manufactured using different batches of Active Pharmaceutical Ingredients (API). If multiple API manufacturers are proposed for the finished product, a commitment to conduct finished product stability studies for 1 production batch using the API from each API manufacturer that is not represented in the finished product stability batches is required.

Multiple primary packaging sites

If more than one primary packaging (PP) site is proposed for registration, stability data from three finished product batches using PP from at least one of these sites must be provided.

For additional PP sites (using the same manufacturing process and container closure system), a commitment is required to conduct stability studies on two (conventional dosage form) or three (critical dosage form) finished product batches.

NON-SITE SPECIFIC STABILITY DATA FOR FINISHED PRODUCT

In the case of technology transfer where site-specific stability data for finished product is not available from the manufacturing site proposed for registration, it may be acceptable to extrapolate the stability data from another site to the site proposed for registration if it can be demonstrated that the submitted data is representative of the proposed finished product manufacturing site (the data must be from primary batches manufactured API intended to be registered in Malaysia).

Finished product is considered representative when the following criteria are fulfilled:

- The quality of the finished product used in the stability batches is comparable (e.g., dissolution profile and established process validation)
- Manufactured using the same formulation
- Manufactured using the same manufacturing process, including equipment type, process parameters and in-process tests. Scientific justification should be provided to demonstrate equivalence between the sites if differences exist.
- Controlled by the same set of specifications
- Packaged in the same type of container closure system

In addition, a commitment to conduct stability studies for finished product for at least one production batch of API is required for each site that is not represented in the submitted stability studies.

If any of the above criteria are not met, site-specific stability data are required to support the application.

6. REFERENCES FOR GENERIC APPLICATION

Applicants are also advised to refer to NPRA's website for the latest registration requirements. In addition, other relevant and latest international guidelines e.g. by EMA, USFDA and ICH should also be referred to complement the ASEAN Guidelines and the DRGD as appropriate.

7. OTHERS

7.1 Classification of products containing Glucosamine, Chondroitin and Methylsulphonylmethane (MSM)

No.	Product		Product Category	Route of Evaluation	Condition on Product Indication	Remark
1.	Products containing Glucosamine	As single active ingredient	OTC	Full evaluation	As adjuvant therapy for osteoarthritis	Products containing glucosamine in combination with other health supplement ingredients are only allowed to be registered for therapeutic purposes and NOT allowed to be registered as Health Supplement Product.
		As combination with Chondroitin and/ or MSM	OTC	Full evaluation	As adjuvant therapy for osteoarthritis	
2.	Products containing Chondroitin	As single ingredient OR In combination with other supplement ingredients	Health supplement	Abridged Evaluation	No therapeutic claims are allowed	-

No.	Product		Product Category	Route of Evaluation	Condition on Product Indication	Remark
3.	Products containing MSM	As single ingredient OR In combination with other supplement ingredients	Health supplement	Abridged Evaluation	No therapeutic claims are allowed	-
		As combination with Chondroitin	Health supplement	Abridged Evaluation	No therapeutic claims are allowed	-

References: Circulars

(i) *Bil. (66) dlm BPFK/02/5/1.3*
Produk yang Mengandungi Glucosamine dan Chondroitin (14 November 2006)

(ii) *Bil. (20) dlm.BPFK/PPP/01/03*
Produk yang mengandungi Glucosamine, Chondroitin dan Methylsulfonylmethane (MSM) (31 December 2008)

7.2 Classification of products containing combination of vitamin and/or mineral

(i) Products containing a combination of vitamin and/or mineral are classified as Health Supplements. Please refer to **Appendix 6**: Guideline on Registration of Health Supplements for daily limit and registration requirements.

(ii) For product containing a combination of vitamin and/or mineral with therapeutic indication:

(a) Product classification is required to determine the category of the said product as different regulatory requirements may apply. Applicant may submit a classification form, which can be downloaded from the NPRA website for classification of product category.

(b) Data/references to support the proposed combination and strength of active ingredients, dosage form, indication and dosing/posology will be required.

(c) Other supporting documents deemed necessary shall be submitted upon request to support the efficacy and safety of the product for the proposed indication.

(d) Approval status (for the same indication) together with the classification of the product in DCA reference countries (United Kingdom, Sweden, France, United States of America, Australia, Canada, Japan and Switzerland) is required.